All In Biotech

Drug Trial Radar · NCT04205812

Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer

A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer (POD1UM-304)

Last checked: Nov 20, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 583 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

583

Actual

Start

Sep 11, 2020

Primary completion

Dec 15, 2023

Study completion May 28, 2026

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
First posted
Dec 19, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy and safety of platinum-based chemotherapy with or without INCMGA00012 in participants with metastatic squamous and nonsquamous non-small cell lung cancer (NSCLC).

Conditions

  • Metastatic Squamous Non-Small Cell Lung Cancer
  • Metastatic Nonsquamous Non-Small Cell Lung Cancer

Interventions

  • RetifanlimabDrug

    INCMGA00012 administered intravenously every 3 weeks on Day 1 of each cycle for up to 35 cycles.

  • PlaceboDrug

    Placebo administered intravenously every 3 weeks on Day 1 of each cycle for up to 35 cycles.

  • PemetrexedDrug

    Pemetrexed administered intravenously every 3 weeks on Day 1 of each cycle.

  • CisplatinDrug

    Cisplatin administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.

  • CarboplatinDrug

    Carboplatin administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.

  • PaclitaxelDrug

    Paclitaxel administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.

  • nab-PaclitaxelDrug

    nab-Paclitaxel administered intravenously every 3 weeks on Days 1, 8, and 15 of each cycle for 4 cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: up to 39.1 months

Locations

140 sites in 17 countries. Site status is shown where the registry gives one.

  • Pacific Cancer Medical Center

    Anaheim, California

  • Innovative Clinical Research Institute

    Whittier, California

  • Reading Hospital and Medical Center

    Reading, Pennsylvania

  • Fundacao Pio Xii Hospital de Cancer de Barretos

    Barretos, Brazil

  • Incan - Instituto Do Cancer - Hospital Pompeia

    Caxias do Sul, Brazil

  • Centro Regional Integrado de Oncologia

    Fortaleza, Brazil

  • Oncosite - Centro de Pesquisa Clinica E Oncologia

    Ijuí, Brazil

  • Clinica de Neoplasias Litoral Ltda

    Itajaí, Brazil

  • Hospital Do Cancer de Londrina

    Londrina, Brazil

  • Instituto Mederi de Pesquisa E Saude

    Passo Fundo, Brazil

  • Hgb - Hospital Giovanni Battista - Mae de Deus Center

    Porto Alegre, Brazil

  • Inca - Instituto Nacional de Cancer

    Rio de Janeiro, Brazil

  • Sao Camilo Oncologia

    S?O Paulo, Brazil

  • Cepho - Centro de Estudos E Pesquisas de Hematologia E Oncologia

    Santo André, Brazil

  • Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto

    São José, Brazil

  • Mc Women'S Health-Nadezhda Eood

    Sofia, Bulgaria

  • Acibadem Cityclinica Mhat Tokuda

    Sofia, Bulgaria

  • Umhat Sv. Ivan Rilski Ead

    Sofia, Bulgaria

  • Mhat Serdika Eood

    Sofia, Bulgaria

  • Multiprofile Hospital For Active Treatment Central Onco Hospital Ood

    Sofia, Bulgaria

  • Shatod Dr Marko Marko - Varna Ltd

    Varna, Bulgaria

  • Hunan Cancer Hospital

    Changsha, China

  • The First Affiliated Hospital Sun Yat-Sen University

    Guangzhou, China

  • Sir Run Run Shaw Hospital Zhejiang University School of Medicine

    Hangzhou, China

  • Hangzhou Cancer Hospital

    Hangzhou, China

  • The First Affiliated Hospital of Zhejiang University

    Hangzhou, China

  • Zhejiang Cancer Hospital

    Hangzhou, China

  • Harbin Medical University Cancer Hospital

    Harbin, China

  • University of Science and Technology of China-First Affiliated Hospital (Anhui Provincial Hospital)

    Hefei, China

  • The Second Hospital of Anhui Medical University

    Hefei, China

  • Jinan Central Hospital

    Jinan, China

  • Linyi Cancer Hospital

    Linyi, China

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, China

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, China

  • Shanghai Chest Hospital

    Shanghai, China

  • General Hospital of Tianjin

    Tianjing, China

  • The Affiliated Cancer Hospital of Xinjiang Medical University

    Ürümqi, China

  • Henan Cancer Hostipal

    Zhengzhou, China

  • Henan Provincial Peoples Hospital

    Zhengzhou, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, China

Showing 40 of 140 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.